Literature DB >> 10374781

Trisomy 3 in gastric lymphomas of extranodal marginal zone B-cell (mucosa-associated lymphoid tissue) origin demonstrated by FISH in intact paraffin tissue sections.

R Blanco1, M Lyda, B Davis, M Kraus, C Fenoglio-Preiser.   

Abstract

Some reports have indicated that trisomy 3 represents a characteristic chromosomal abnormality found in lymphomas arising in mucosa-associated lymphoid tissues (MALT)/extranodal marginal zone B-cells (MZBC). Traditional cytogenetic analysis of metaphase preparations is cumbersome and not always possible, especially in those situations in which the diagnosis in not suspected before a biopsy. Our aim is to use a relatively simple method to evaluate trisomy 3 in paraffin-embedded, formalin-fixed tissue, using fluorescence in situ hybridization (FISH) on intact tissue sections. Formalin-fixed, paraffin-embedded archival tissues from 30 cases (27 lymphoma and 3 chronic gastritis cases) were hybridized with a chromosome 3 specific alpha-satellite probe (ONCOR, Gaithersburg, MD). Three of four cases of gastric MZBC/MALT lymphoma revealed trisomy 3. Ten cases of lymphoma of possible or probable MZBC origin were examined, and four revealed trisomy 3. Five of 13 non-MZBC lymphomas revealed trisomy 3. None of the chronic gastritis cases nor normal tonsil cases revealed trisomy 3. Our results, using a different methodological approach, confirm the findings of others that trisomy 3 is an abnormality found in a significant proportion of lymphomas of MZBC origin. Our approach also makes possible interphase cytogenetic analysis (by FISH) of routinely processed formalin-fixed, paraffin-embedded tissues, without the need to disaggregate cells. It thus may facilitate genetic analysis on specimens previously deemed unsuitable for such analysis, particularly when tissue quantity is limited.

Entities:  

Mesh:

Year:  1999        PMID: 10374781     DOI: 10.1016/s0046-8177(99)90098-9

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  7 in total

1.  Trisomy 3 may predict a poor response of gastric MALT lymphoma to Helicobacter pylori eradication therapy.

Authors:  Sawako Taji; Kenichi Nomura; Yosuke Matsumoto; Hideaki Sakabe; Naohisa Yoshida; Shoji Mitsufuji; Kazuhiro Nishida; Shigeo Horiike; Shigeo Nakamura; Masuji Morita; Masafumi Taniwaki
Journal:  World J Gastroenterol       Date:  2005-01-07       Impact factor: 5.742

2.  18q21 Rearrangement and trisomy 3 in extranodal B-cell lymphomas: a study using a fluorescent in situ hybridisation technique.

Authors:  Yan-Chin Tai; Jin-Ai Mary Anne Tan; Suat-Cheng Peh
Journal:  Virchows Arch       Date:  2004-09-09       Impact factor: 4.064

3.  Fluorescence in situ hybridization detection of chromosome IGH/BCL2 translocations from paraffin-embedded tissue: evaluation in follicular lymphoma.

Authors:  Yuko Hirose; Yasufumi Masaki; Mamoru Ozaki
Journal:  Int J Hematol       Date:  2003-08       Impact factor: 2.490

4.  Unfavourable prognosis of patients with trisomy 18q21 detected by fluorescence in situ hybridisation in t(11;18) negative, surgically resected, gastrointestinal B cell lymphomas.

Authors:  J Krugmann; A Tzankov; S Dirnhofer; F Fend; R Greil; R Siebert; M Erdel
Journal:  J Clin Pathol       Date:  2004-04       Impact factor: 3.411

Review 5.  Mucosa-associated lymphoid tissue lymphomas.

Authors:  M Gospodarowicz; R Tsang
Journal:  Curr Oncol Rep       Date:  2000-03       Impact factor: 5.945

Review 6.  Recent Advances in the Genetic of MALT Lymphomas.

Authors:  Juan José Rodríguez-Sevilla; Antonio Salar
Journal:  Cancers (Basel)       Date:  2021-12-30       Impact factor: 6.639

7.  Management of gastric mucosa-associated lymphoid tissue lymphoma in patients with extra copies of the MALT1 gene.

Authors:  Masaya Iwamuro; Ryuta Takenaka; Masahiro Nakagawa; Yuki Moritou; Shunsuke Saito; Shinichiro Hori; Tomoki Inaba; Yoshinari Kawai; Tatsuya Toyokawa; Takehiro Tanaka; Tadashi Yoshino; Hiroyuki Okada
Journal:  World J Gastroenterol       Date:  2017-09-07       Impact factor: 5.742

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.